TREATMENTS

Child Boards

[-] AUBAGIO (teriflunomide)

[-] AVONEX (interferon beta-1a)

[-] BETASERON (interferon beta-1b, Betaferon, Extavia)

[-] COPAXONE (glatiramer acetate)

[-] GILENYA (fingolimod, FTY720)

[-] GLATOPA (generic Copaxone - 20 mg/ml daily)

[-] LEMTRADA (Campath, alemtuzumab)

[-] MAVENCLAD (cladribine)

[-] MAYZENT (siponimod)

[-] NOVANTRONE (mitoxantrone)

[-] OCREVUS (ocrelizumab)

[-] PLEGRIDY (pegylated interferon beta-1a)

[-] REBIF (interferon beta-1a)

[-] TECFIDERA (dimethyl fumarate, BG-12, Fumaderm)

[-] TYSABRI (natalizumab)

[-] AMPYRA (dalfampridine)

Topics

(1/20) > >>

[1] DRUG INFORMATION

[2] Non-approved (off-label) treatments used for MS disease modification

[3] (Neurology Now) Guide to choosing a disease-modifying therapy for MS

[4] Use of Mavenclad, Ocrevus rising in Europe

[5] Zinbryta (daclizumab) pulled from market due to safety concerns

[6] Ofatumumab

[7] (Abst.) Efficacy and safety of ozanimod in MS

[8] Rituxan (rituximab)

[9] What's new in the MS drug pipeline

Navigation

[0] Up one level

[#] Next page

Go to full version